Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05918432

Determining Patterns In Study Experiences of Neuroblastoma Patients

Historically, participation in clinical research is highly skewed towards particular demographic groups of people.

This study will invite several participants to gather a wide range of information on clinical trial experiences for neuroblastoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of neuroblastoma.

The data collected from this study will help improve future outcomes for all neuroblastoma patients as well as those in under-represented demographic groups.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Neuroblastoma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors Neuroectodermal Tumors, Primitive Neuroectodermal Tumors, Primitive, Peripheral

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Power Life Sciences

San Francisco, California, 94107, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of neuroblastoma
  • Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
  • Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.

Exclusion criteria

  • Women of childbearing potential without a negative pregnancy test; or women who are lactating.
  • Any serious and/or unstable pre-existing medical disorders
  • Enrolled in another research study

Treatment and study plan

Primary outcomes

  1. Number of patients who decide to enroll in a neuroblastoma clinical trial

    Time frame: 3 months

  2. Rate of patients who remain in neuroblastoma clinical trial to trial completion

    Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Michael B Gill

CONTACT

[email protected]

(415) 900-4227

Sponsors and collaborators

Lead sponsor

Power Life Sciences Inc.

Industry

Registry information

Official study title

Neuroblastoma Clinical Trials: Looking at Patterns About How Patients Feel About Participating in Clinical Trials

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jun 26, 2023
Registry last updated
Jun 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.